Next‐generation ALK inhibitor vs crizotinib
Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer
It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).
1 finding from 1 review
- Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes onlyHR 1.1 [0.72, 1.68]1 study · 303 participantsVery low